Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Prostate cancer remains a leading cause of cancer-related mortality in men globally.
• There is an ongoing need for novel therapeutic agents to combat this disease effectively.

Purpose of the Study:

• To investigate valeric acid (VA) as a potential HDAC inhibitor for prostate cancer treatment.
• To evaluate the anti-cancer efficacy and mechanism of action of VA in prostate cancer cells and in vivo models.

Main Methods:

• Theoretical and experimental validation of valeric acid (VA) as a histone deacetylase (HDAC) inhibitor.
• In vitro studies using 2D and 3D cell culture systems to assess VA's cytotoxicity and effects on prostate cancer cells versus normal cells.
• Analysis of key protein expression (E2F1/E2F3) and enzyme activity (CASP3) following VA treatment.
• In vivo studies using mouse models to confirm anti-cancer activity and chemosensitizing properties.

Main Results:

• Valeric acid (VA) was confirmed as a HDAC3 inhibitor.
• VA demonstrated significant cytotoxicity against prostate cancer cells with minimal toxicity to normal cells.
• VA treatment led to the inhibition of E2F1/E2F3 expression and increased CASP3 activity.
• In vivo studies supported VA's anti-cancer effects and its potential as a chemosensitizer by promoting apoptosis.

Conclusions:

• Valeric acid (VA) functions as a HDAC3 inhibitor, exhibiting anti-cancer properties against prostate cancer.
• VA exerts its effects by modulating the E2F1/E2F3/CASP3 signaling pathway, leading to apoptosis.
• VA shows promise as a therapeutic agent or chemosensitizer for prostate cancer treatment due to its targeted efficacy and low toxicity.